Wenxin Zheng, M.D., Tenured Professor of Pathology, Obstetrics and Gynecology, American board certified pathologist, graduated from Shanghai Medical College Fudan University and trained at Columbia University, Cornell University, and Brown University Medical Centers in anatomic pathology and gynecologic pathology, Selected by US News and World Report in 2013 as one of America's top pathologists, Dr. Zheng is an internationally recognized gynecologic pathologist with outstanding expertise in every aspect of gynecologic pathology. Dr. Zheng’s main research contributions include endometrial serous carcinogenesis and precancerous lesion endometrial glandular dysplasia, cell origin of low-grade ovarian serous carcinoma, hormonal etiology of ovarian epithelial cancers, and tubal contribution of ovarian endometriosis and its associated ovarian cancers. In addition to these, Dr. Zheng has created a novel approach called "One Stop Cervical Care (OSCC)" to diagnose and treat cervical precancers.
- Medical School
- Shanghai Medical College of Fudan University (1982)
- Hospital of Obstetrics and Gynecology (1983), Obstetrics & Gynecology
- Hospital of Obstetrics and Gynecology (1986), Obstetrics & Gynecology
- Columbia University Medical Center (1989), Molecular Reproduction
- Cornell New York Presbyterian Hospital (1995), Pathology
- Brown University Woman & Infant Hospital (1996), Gynecologic Pathology
- Biomarkers to aid the diagnosis of gynecologic cancers
- Cervical cancer: suitable model of cervical cancer screening, effective intervention, and prevention in developing countries.
- Endometrial serous carcinoma: carcinogenesis, early detection and prevention
- Ovarian cancer early detection and prevention
- Tubal origin of ovarian endometriosis and its related cancer development
- Tubal secretory cell biology
- Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?
- Fadare O, Roma AA, Parkash V, Zheng W, Walavalkar V Adv Anat Pathol 2017 Sep
- Pathological findings in explanted vaginal mesh.
- Li L, Wang X, Park JY, Chen H, Wang Y, Zheng W Hum. Pathol. 2017 Sep
- Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
- Qiu C, Lu N, Wang X, Zhang Q, Yuan C, Yan S, Dongol S, Li Y, Sun X, Sun C, Zhang Z, Zheng W, Kong B Gynecol. Oncol. 2017 Sep
- Malignant Female Adnexal Tumor of Probable Wolffian Origin: Case Report and Literature Review.
- Hong S, Cui J, Li L, Buscema J, Liggins C, Zheng W Int. J. Gynecol. Pathol. 2017 Jul
- Endometrial Carcinoma With Trophoblastic Components: Clinicopathologic Analysis of a Rare Entity.
- Rawish KR, Buza N, Zheng W, Fadare O Int. J. Gynecol. Pathol. 2017 Jun
- BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
- Wang Y, Wang Y, Wei L, Hong S, Zhao M, Zhang X, Zheng W J Ovarian Res 2017 Mar 10 1 12
- Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.
- Fan R, Wang Y, Wang Y, Wei L, Zheng W Am J Transl Res 2017 9 3 1483-1491
- Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization.
- Zhang L, Yang B, Zhang A, Zhou A, Yuan J, Wang Y, Sun L, Cao H, Wang J, Zheng W J. Med. Virol. 2016 Apr
- Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
- Wang Y, Wang Y, Zhang Z, Park JY, Guo D, Liao H, Yi X, Zheng Y, Zhang D, Chambers SK, Zheng W Oncotarget 2016 Jan
- Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.
- Wang Y, Li L, Wang Y, Tang SN, Zheng W Am J Transl Res 2016 8 1 230-8
Many chapters as leading or co-authors. In Gynecologic and Obstetrics Pathology
Wenxin Zheng et al., (Ed.) (2013). Beijing,China, Science Press